Sanofi's $470M Vigil Neuroscience, Inc. acquisition highlights VG-3927's potential in Alzheimer's. Click here to find out why ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Jon Ellis and Simon Vanstone, PhD, go behind the headlines to explore the latest M&A activity and what tariffs and funding changes could mean for mRNA and beyond.

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

MoonLake jumps 18% after a report says MRK made a $3 billion-plus offer earlier this year, with talks potentially set to resume.

Disappointing results for iluzanebart come shortly after Vigil Neuroscience struck a buy-out deal with Sanofi, but analysts ...

A phase 2 study of Vigil Neuroscience’s iluzanebart has missed its biomarker and efficacy endpoints, prompting the ...

Sanofi and BMS paid big money for rare disease and cancer assets, while Regeneron got in the obesity game; AstraZeneca, Gilead and Amgen shone at ASCO; RFK Jr. and the CDC appeared to disagree over ...

Sanofi is set to acquire Blueprint Medicines, a US-based biopharmaceutical company specialising in systemic mastocytosis.

This article summarizes recent developments in the health sector, including major acquisitions, drug trial results, and ...

Here are the five things you need to know, including Lyra's good news, Sanofi's acquisition, Mass. biotech jobs, inside Market Basket's board, AI, and hiring entry-level jobs.